EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies

Wenjun Meng iD, Yan Liu, Haoran Zhang, Manting Wang, Xiaoli Mu, Ziqi Zhang, Yan Tie

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27104484 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Wenjun Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Melanoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted inhibition of the MAPK pathway with BRAF and MEK inhibitors (BRAFi/MEKi) produces rapid tumor regressions in BRAF V600-mutant melanoma, yet most patients ultimately develop acquired resistance. Resistance is not solely a tumor-cell-intrinsic phenomenon; it is accompanied by time-dependent remodeling of the tumor immune microenvironment (TIME) that can shape sensitivity to immune checkpoint inhibitors (ICIs) and inform rational combination or sequencing strategies. Early during MAPK inhibition, melanomas often display increased melanoma antigen expression and enhanced CD8+ T-cell infiltration, along with reduced immunosuppressive cytokines, suggesting a transient “immune-permissive” window. However, the same period can show induction of PD-L1 and T-cell exhaustion markers, foreshadowing adaptive immune resistance. At progression, immune-favorable features may diminish and immune evasion mechanisms, such as impaired antigen presentation and MHC-I downregulation, can become prominent and associate with resistance to immunotherapy. Here we review the temporal dynamics of TIME under MAPK inhibition, mechanistic links between resistance programs and immune remodeling, including signaling adaptation, focal adhesion/FAK signaling, dendritic cell dysfunction, antigen-presentation defects, and lymphatic/perilymphatic adipose remodeling, and practical biomarker opportunities across baseline, on-treatment, and progression timepoints. We also summarize emerging therapeutic strategies for post-resistance disease, including optimized ICI combinations, triple therapy concepts, and novel approaches such as combining FAK inhibition with RAF-MEK “clamp” therapy. Finally, we highlight key gaps and propose a framework for longitudinal sampling, standardized multi-omics integration, and TIME-informed trial design. The key distinguishing feature of this review is its time-resolved perspective on TIME remodeling, which links baseline immune contexture, early treatment-induced immune permissiveness, and the immune-evasive state that emerges during acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentDrug Resistance, NeoplasmProtein Kinase InhibitorsMelanomaProto-Oncogene Proteins B-rafHumansAnimalsBiomarkers, TumorImmunotherapy

Stichwörter der Autor:innen

BRAF inhibitorMEK inhibitoracquired resistanceimmune escapemelanomatumor immune microenvironment

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, human

Autor:innen und Institutionen

  • Department of Pain Management, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Outpatient Department, West China Hospital, Sichuan University, Chengdu 610041, China.
  • West China School of Medicine, Sichuan University, Chengdu 610041, China.
  • Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Wenjun Meng

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Meng, W., Liu, Y., Zhang, H., Wang, M., Mu, X., Zhang, Z., & Tie, Y. (2026). Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27104484

Vancouver

Meng W, Liu Y, Zhang H, Wang M, Mu X, Zhang Z, et al. Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27104484

BibTeX
@article{Meng2026,
  author = {Meng, Wenjun and Liu, Yan and Zhang, Haoran and Wang, Manting and Mu, Xiaoli and Zhang, Ziqi and Tie, Yan},
  title = {Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27104484}
}
Kostenlos starten →